Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 19 de 19
Filtrar
Mais filtros










Intervalo de ano de publicação
9.
Br J Dermatol ; 179(5): 1163-1167, 2018 11.
Artigo em Inglês | MEDLINE | ID: mdl-29430633

RESUMO

A 17-year-old male presented with a large sebaceous naevus (SN) comprising part of his right face and scalp and a speckled lentiginous naevus (SLN) on his left trunk, hip, neck and scalp with a checkerboard pattern. His right oral hemimucosa showed extensive papillomatous lesions, which were contiguous with the upper-lip SN lesions. He also showed extracutaneous manifestations including cardiac, musculoskeletal and ocular alterations. Internally, he had developed two primary rhabdomyosarcomas. DNA samples of the SN, SLN, oral papillomatous hyperplasia and both rhabdomyosarcomas were analysed by Sanger sequencing. An HRAS c.37G>C mutation was detected in all of them. Skin and blood DNA were wild-type. Phacomatosis pigmentokeratotica (PPK) is characterized by the association of an SN with a papular naevus spilus and extracutaneous manifestations. Until recently, the aetiopathogenetic hypothesis of didymosis was accepted. However, in 2013 Groesser et al. proved the existence of an activating HRAS mutation as the cause of this syndrome. A higher incidence of cancer has been observed in germline RASopathies. Furthermore, up to 30% of human cancers show dysregulation of the Ras-Raf-MEK-ERK pathways. In our patient, an HRAS mosaic mutation explains not only the cutaneous but also the extracutaneous manifestations. To our knowledge this is the first described case of PPK in which the existence of an HRAS mosaic mutation is the confirmed cause of rhabdomyosarcoma. Furthermore, the HRAS c.37G>C mutation has never been related to any type of rhabdomyosarcoma. Mosaicisms could be underdiagnosed causes of childhood tumours. As dermatologists we stand in a privileged position of being able to detect these alterations.


Assuntos
Neoplasias Primárias Múltiplas/genética , Nevo Pigmentado/genética , Proteínas Proto-Oncogênicas p21(ras)/genética , Rabdomiossarcoma/genética , Neoplasias Cutâneas/genética , Adolescente , Análise Mutacional de DNA , Humanos , Masculino , Mosaicismo , Neoplasias Primárias Múltiplas/patologia , Nevo Pigmentado/patologia , Rabdomiossarcoma/patologia , Pele/patologia , Neoplasias Cutâneas/patologia
11.
Br J Dermatol ; 178(3): 786-789, 2018 03.
Artigo em Inglês | MEDLINE | ID: mdl-28222222

RESUMO

A 65-year-old pluripathological woman attended our hospital with a cutaneous eruption of sudden appearance after vancomycin treatment. She presented targetoid lesions affecting approximately 25-30% of her body surface, large erosions with mucosal lesions and positive Nikolsky sign. Under the initial clinical suspicion of toxic epidermal necrolysis (TEN), and considering the recent literature of successful use of etanercept in these cases, she was treated with a single dose of this antitumour necrosis factor (anti-TNF) agent. Subsequently, the exanthema progression stopped and resolution of the lesions happened in a few days. Later on, histopathology revealed a subepidermal blister with dense neutrophilic infiltrate and linear deposits of immunoglobulin A (IgA) on the dermoepidermal junction, allowing us to establish the diagnosis of drug-induced linear IgA dermatosis mimicking TEN. Linear IgA dermatosis can have severe clinical manifestations, even mimicking TEN, and can have high mortality, especially in drug-induced cases. We have not found any other report of linear IgA dermatosis treated with etanercept in the English literature. Anti-TNF medications could represent useful therapeutic alternatives in this dermatosis.


Assuntos
Fármacos Dermatológicos/uso terapêutico , Etanercepte/uso terapêutico , Dermatose Linear Bolhosa por IgA/diagnóstico , Síndrome de Stevens-Johnson/diagnóstico , Idoso , Antibacterianos/efeitos adversos , Diagnóstico Diferencial , Feminino , Humanos , Dermatose Linear Bolhosa por IgA/tratamento farmacológico , Síndrome de Stevens-Johnson/tratamento farmacológico , Resultado do Tratamento , Vancomicina/efeitos adversos
14.
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...